Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity

被引：0
|
作者：
Gruber, M. L. [1 ,2 ,3 ]
Raza, S. [1 ,2 ,3 ]
Gruber, D. [1 ,2 ,3 ]
Narayana, A. [1 ,2 ,3 ]
机构：
[1] NYU, Ctr Clin Canc, New York, NY USA
[2] NYU, Med Ctr, New York, NY 10016 USA
[3] NYU, Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2017
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correlation of treatment effects on progression-free survival at 6 months (PFS-6) and overall survival (OS) in patients with newly diagnosed glioblastoma (GBM).
    Ye, X.
    Grossman, S. A.
    Desideri, S.
    Piantadosi, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [32] Combining progression-free survival and overall survival as a novel composite endpoint for glioblastoma trials
    Trippa, Lorenzo
    Wen, Patrick Y.
    Parmigiani, Giovanni
    Berry, Donald A.
    Alexander, Brian M.
    [J]. NEURO-ONCOLOGY, 2015, 17 (08) : 1106 - 1113
  • [33] Five-year survival data in newly diagnosed glioblastoma treated with radiotherapy along with concurrent and adjuvant temozolomide
    Wadasadawala, T.
    Jalali, R.
    Munshi, A.
    Gupta, T.
    Kalyani, N.
    Menon, H.
    Sarin, R.
    Goel, A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [34] AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
    Chinot, O. L.
    Rouge, T. de la Motte
    Moore, N.
    Zeaiter, A.
    Das, A.
    Phillips, H.
    Modrusan, Z.
    Cloughesy, T.
    [J]. ADVANCES IN THERAPY, 2011, 28 (04) : 334 - 340
  • [35] AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme
    O. L. Chinot
    T. de La Motte Rouge
    N. Moore
    A. Zeaiter
    A. Das
    H. Phillips
    Z. Modrusan
    T. Cloughesy
    [J]. Advances in Therapy, 2011, 28 : 334 - 340
  • [36] RETROSPECTIVE EVALUATION OF OVERALL SURVIVAL AND PROGRESSION FREE SURVIVAL IN PATIENTS WITH GLIOBLASTOMA COMPARING 6 VS 12 CYCLES OF ADJUVANT TEMOZOLOMIDE
    Perez, D. Martinez
    Mendez, B. Deben
    Roldan, M. Rodriguez
    Botella, M. Garrido
    Cuesta, J. Garcia
    Barbas, J. Pedregosa
    Aguirre, Y. Vilches
    Marin, V. Martinez
    [J]. NEURO-ONCOLOGY, 2022, 24
  • [37] Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
    Peter G. Zaki
    Sanjeev Herr
    Matthew J. Shepard
    [J]. Journal of Neuro-Oncology, 2024, 167 : 363 - 364
  • [38] Letter to the editor: Dexamethasone and overall survival and progression free survival in patients with newly diagnosed glioblastoma: a meta-analysis
    Zaki, Peter G.
    Herr, Sanjeev
    Shepard, Matthew J.
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2024, 167 (02) : 363 - 364
  • [39] Correlation of molecular subtypes with survival in AVAglio (bevacizumab [Bv] and radiotherapy [RT] and temozolomide [T] for newly diagnosed glioblastoma [GB])
    Phillips, Heidi
    Sandmann, Thomas
    Li, Congfen
    Cloughesy, Timothy Francis
    Chlnot, Olivier L.
    Wick, Wolfgang
    Nishikawa, Ryo
    Mason, Warren P.
    Henriksson, Roger
    Saran, Frank
    Lai, Albert
    Moore, Nicola
    Hegde, Priti S.
    Abrey, Lauren E.
    Bourgon, Richard
    Garcia, Josep
    Bais, Carlos
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Olaparib plus bevacizumab improves progression-free survival in ovarian cancer
    Gourd, Elizabeth
    [J]. LANCET ONCOLOGY, 2020, 21 (02): : E71 - E71
12345